Community West Bank opens new Santa Maria Branch
Community West Bancshares, parent company of Community West Bank, announced the opening of its full-service Santa Maria branch at 122 Betteravia Road on Jan. 17, replacing its 2615 S. Miller St. location. The move continues its Central Coast expansion after the bank opened its first full-service San Luis Obispo branch at 4464 Broad St. in Read More →
Patent ruling in favor of Amgen has shares skyrocketing
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Taylor Frigon launches locally managed mutual fund
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Limoneira reports strong revenue growth
Santa Paula agribusiness Limoneira reported increased revenues for the fourth quarter and fiscal year 2016, exceeding its guidance with an operating income of $9.2 million. Net income applicable to common stock, after preferred dividends, was $7.4 million for the year, or 52 cents per common share, up from $6.4 million in 2015. The company had announced expectations of operating Read More →
Amgen updates agreement with DaVita for dialysis treatment
Thousand Oaks biotech company Amgen entered into a six-year supply agreement with DaVita for dialysis treatments, the company announced on Jan. 9. Under the terms of the new agreement, Amgen will supply DaVita with Epogen and Aranesp for agents to stimulate red blood cells in dialysis treatment in the United States and Puerto Rico. The Read More →
Amgen partners with Immatics Biotechnologies to develop cancer drugs
Thousand Oaks biotech company Amgen formed a potential $500 million partnership with Immatics Biotechnologies GmbH to research and develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers, the company announced on Jan. 9. Under the terms of the agreement, Immatics will receive $30 million upfront and can receive more than $500 million in development, regulatory Read More →
Rate hikes will be boon for tri-county banks in 2017
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
